Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + BP102 + XELOX in Metastatic Colorectal Cancer
NCT03645876Phase 2Terminated
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in metastatic colorectal cancer (mCRC), sponsored by Hengrui. Started Nov 2018; status: terminated.
02
Drugs
camrelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03645876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03645876.